Voyager Therapeutics (VYGR) Net Cash Flow Growth (3y) (2017 - 2026)
Voyager Therapeutics (VYGR) Net Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 32.17% |
| 10 | Voyager Therapeutics | 184.74 Mn | 43.26 Mn | - | -28.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.66% |
| Dec 31, 2025 | 101.99% |
| Sep 30, 2025 | -40.39% |
| Jun 30, 2025 | 16.96% |
| Mar 31, 2025 | -38.32% |
| Dec 31, 2024 | -107.30% |
| Sep 30, 2024 | 97.60% |
| Jun 30, 2024 | -1,042.12% |
| Mar 31, 2024 | 78.17% |
| Dec 31, 2023 | 27.69% |
| Sep 30, 2023 | -289.89% |
| Jun 30, 2023 | -4.64% |
| Mar 31, 2023 | 28.28% |
| Dec 31, 2022 | -14.87% |
| Sep 30, 2022 | 88.77% |
| Jun 30, 2022 | -17.26% |
| Mar 31, 2022 | -39.86% |
| Dec 31, 2021 | 8.10% |
| Sep 30, 2021 | 28.57% |
| Jun 30, 2021 | 26.00% |